These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Many in VOICE trial didn't use provided prevention products. AIDS Policy Law; 2015 Mar; 30(4):3. PubMed ID: 26094276 [No Abstract] [Full Text] [Related]
6. Protease inhibitors and non-nucleoside reverse transcriptase inhibitors have a comparable effect on the CD4 cell change after switching to tenofovir-based regimens. van Leth F; Prins JM; Lange JM; Geerlings SE AIDS; 2005 Oct; 19(15):1722-3. PubMed ID: 16184059 [No Abstract] [Full Text] [Related]
7. Unethical clinical trials in Thailand: a community response. Jintarkanon S; Nakapiew S; Tienudom N; Suwannawong P; Wilson D Lancet; 2005 May 7-13; 365(9471):1617-8. PubMed ID: 15885287 [No Abstract] [Full Text] [Related]
8. Can AIDS drug also prevent HIV infection? AIDS Read; 2004 Jan; 14(1):14. PubMed ID: 14959699 [No Abstract] [Full Text] [Related]
9. Promising prevention approaches: tenofovir gel and prophylactic use of antiretroviral medications. Krakower D; Mayer KH Curr HIV/AIDS Rep; 2011 Dec; 8(4):241-8. PubMed ID: 22002729 [TBL] [Abstract][Full Text] [Related]
10. Women testing tenofovir for HIV prevention. AIDS Patient Care STDS; 2005 Feb; 19(2):128. PubMed ID: 15747428 [No Abstract] [Full Text] [Related]
11. [3 years' data of tenofovir. Confirmed as a valuable building block]. MMW Fortschr Med; 2004 Apr; 146 Spec No 1():30-1. PubMed ID: 15373042 [No Abstract] [Full Text] [Related]
12. Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations. Valer L; MartÃn-Carbonero L; de Mendoza C; Corral A; Soriano V AIDS; 2004 Oct; 18(15):2094-6. PubMed ID: 15577635 [TBL] [Abstract][Full Text] [Related]
13. Oral tenofovir arm of VOICE trial discontinued early. McEnery R IAVI Rep; 2011; 15(5):21. PubMed ID: 22121550 [No Abstract] [Full Text] [Related]
14. Unethical clinical trials in Thailand: a community response. Loff B; Jenkins C; Ditmore M; Overs C; Barbero R Lancet; 2005 May 7-13; 365(9471):1618-9. PubMed ID: 15889464 [No Abstract] [Full Text] [Related]
15. Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen. Kuritzkes DR J Infect Dis; 2005 Dec; 192(11):1867-8. PubMed ID: 16267755 [No Abstract] [Full Text] [Related]
16. Impact of Tenofovir gel as a PrEP on HIV infection: a mathematical model. Rahman SM; Vaidya NK; Zou X J Theor Biol; 2014 Apr; 347():151-9. PubMed ID: 24380779 [TBL] [Abstract][Full Text] [Related]
17. Disinhibition and risk compensation: scope, definitions, and perspective. Hogben M; Liddon N Sex Transm Dis; 2008 Dec; 35(12):1009-10. PubMed ID: 18936724 [No Abstract] [Full Text] [Related]
18. Impact of tenofovir versus abacavir on HIV-related endothelial dysfunction. Francisci D; Falcinelli E; Belfiori B; Petito E; Fierro T; Baldelli F; Gresele P AIDS Patient Care STDS; 2011 Oct; 25(10):567-9. PubMed ID: 21851265 [No Abstract] [Full Text] [Related]
19. An open-label pilot study to determine the efficacy of lopinavir/ritonavir and tenofovir DF in the treatment of HIV-infected patients experiencing first virologic failure on a non-nucleoside-based regimen. Pierone G; Mieras J; Bulgin-Coleman D; Kantor C; Shearer J; Fontaine L; Fath M AIDS Patient Care STDS; 2008 Apr; 22(4):263-6. PubMed ID: 18422459 [No Abstract] [Full Text] [Related]
20. Tenofovir: a pill to prevent HIV? Bonn D Lancet Infect Dis; 2005 Feb; 5(2):78. PubMed ID: 15702509 [No Abstract] [Full Text] [Related] [Next] [New Search]